Investigational drug · Phase 3
JMKX001899
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for NSCLC (Non-small Cell Lung Cancer).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "JMKX001899"
First trial start
2025
Dec 31, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JMKX001899", any sponsor or status.
Conditions studied
As listed on its trial records.
- NSCLC (Non-small Cell Lung Cancer)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "JMKX001899" as an intervention, largest first.
- Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLCPivotal-lookingNot yet recruiting
JemincareIndustry
NCT07242274 · 472 participants (planned) · Start Dec 31, 2025 · Primary completion Dec 31, 2027
Drug: JMKX001899; Docetaxel · For: NSCLC (Non-small Cell Lung Cancer)
Sites: Beijing, China
JemincareIndustry
NCT06348290 · 72 participants (planned) · Start Apr 1, 2024 · Primary completion May 31, 2024
Drug: JMKX001899; Itraconazole and 5 more · For: Solid Tumor, Adult
JemincareIndustry
NCT06946927 · 72 participants (planned) · Start Jun 6, 2025 · Primary completion Feb 2026
Drug: JMKX001899; IN10018 and 2 more · For: NSCLC (Advanced Non-small Cell Lung Cancer)
Sites: Guangzhou, China
- To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy SubjectsStatus unknown
JemincareIndustry
NCT06473948 · 27 participants (planned) · Start Jul 10, 2024 · Primary completion Sep 24, 2024
Drug: JMKX001899; JMKX001899 and 2 more · For: Solid Tumor, Adult
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for NSCLC (Non-small Cell Lung Cancer)
- AndamertinibPLB1004Phase 38 trials
Avistone Biotechnology Co., Ltd. · Non-Small-Cell Lung Cancer, NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer
- OSE2101Phase 32 trials
OSE Immunotherapeutics · Patients With Non-Small Cell Lung Cancer, Solid Advanced Tumor, Lymphoma
- SugemalimabPhase 32 trials
Akeso · NSCLC (Non-small Cell Lung Cancer), Extranodal NK/T-cell Lymphoma
- IAM1363Phase 21 trial
Iambic Therapeutics, Inc · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer
- OSE-279Phase 21 trial
OSE Immunotherapeutics · Solid Advanced Tumor, Lymphoma, NSCLC (Non-small Cell Lung Cancer)
- TXN10128Phase 21 trial
Txinno Bioscience Inc. · NSCLC (Non-small Cell Lung Cancer)
- YH42946Phase 21 trial
Yuhan Corporation · NSCLC (Non-small Cell Lung Cancer), Solid Tumor
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.